Clinical research progress of amyloid and tau protein PET imaging in dementia

Huiwei Zhang; Chuantao Zuo

doi:10.13406/j.cnki.cyxb.002800

您当前的位置：

首页 >

文章列表页 >

Clinical research progress of amyloid and tau protein PET imaging in dementia

Neuroimaging diagnosis | 更新时间：2022-06-24

- Clinical research progress of amyloid and tau protein PET imaging in dementia
- Journal of Shanxi Agricultural Sciences Vol. 46, Issue 7, Pages: 813-817(2021)
- 作者机构：
  
  复旦大学附属华山医院PET中心，上海　200235
- 作者简介：
- 基金信息：
- DOI：10.13406/j.cnki.cyxb.002800
  CLC： R445.5
- Published：28 July 2021，
  
  Received：04 March 2021，
扫描看全文
Huiwei Zhang, Chuantao Zuo. Clinical research progress of amyloid and tau protein PET imaging in dementia. [J]. Journal of Shanxi Agricultural Sciences 46(7):813-817(2021)
DOI：

Huiwei Zhang, Chuantao Zuo. Clinical research progress of amyloid and tau protein PET imaging in dementia. [J]. Journal of Shanxi Agricultural Sciences 46(7):813-817(2021) DOI： 10.13406/j.cnki.cyxb.002800.

摘要

人口老龄化导致痴呆，特别是阿尔茨海默病（Alzheimer's disease，AD）的发病率、患病率呈明显上升态势。正电子发射断层显像（positron emission tomography，PET）是近年来蓬勃发展的分子影像学诊断技术之一。在痴呆领域中，以神经病理学为基础，放射性标记的淀粉样蛋白和tau蛋白正电子显像剂可以客观地检测脑内异常蛋白沉积分布情况，可广泛应用于AD的早期诊断与鉴别诊断、疾病进展与预后评估等方面。本文主要针对淀粉样蛋白和tau蛋白正电子显像剂的发展和临床研究现状进行综述。

Abstract

The aging of the population has led to a significant increase in the incidence and prevalence rate of dementia

especially Alzheimer's disease (AD). Positron emission tomography (PET) is one of the most advanced molecular imaging diagnostic techniques in recent years. In the field of dementia

based on neuropathology

radio-labeled molecular probes of amyloid and tau tracer can objectively detect the distribution of abnormal protein deposition in the brain

which can be widely used in the early diagnosis and differential diagnosis of AD

disease progression and prognosis assessment. This paper focuses on the development and clinical research status of molecular probes for amyloid and tau protein.

关键词

阿尔茨海默病诊断正电子显像剂

Keywords

Alzheimer's diseasediagnosispositron imaging agent

references

中国痴呆与认知障碍指南写作组, 中国医师协会神经内科医师分会认知障碍疾病专业委员会. 2018中国痴呆与认知障碍诊治指南(一)：痴呆及其分类诊断标准[J]. 中华医学杂志, 2018, 98(13):965-970.

Stephen R, Organiztion FWH. Risk reduction of cognitive decline and dementia: WHO guidelines[M]. Geneva: World Health Organization, 2019.

Jia L, Quan M, Fu Y, et al. Dementia in China: epidemiology, clinical management, and research advances[J]. Lancet Neurol, 2020, 19(1):81-92.

Rowe CC, Ellis KA, Rimajova M, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle(AIBL)study of aging[J]. Neurobiol Aging, 2010, 31(8):1275-1283.

Langa KM, Levine DA. The diagnosis and management of mild cognitive impairment: a clinical review[J]. JAMA, 2014, 312(23):2551-2561.

Dubois B, Epelbaum S, Nyasse F, et al. Cognitive and neuroimaging features and brain beta-amyloidosis in individuals at risk of Alzheimer's disease(INSIGHT-preAD): a longitudinal observational study[J]. Lancet Neurol, 2018, 17(4):335-346.

Chandra A, Valkimadi PE, Pagano G, et al. Applications of amyloid, tau, and neuroinflammation PET imaging to Alzheimer's disease and mild cognitive impairment[J]. Hum Brain Mapp, 2019, 40(18):5424-5442.

Wiseman SJ, Meijboom R, Valdes Hernandez MDC, et al. Longitudinal multi-centre brain imaging studies: guidelines and practical tips for accurate and reproducible imaging endpoints and data sharing[J]. Trials, 2019, 20(1):21.

Clark CM, Pontecorvo MJ, Beach TG, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: a prospective cohort study[J]. Lancet Neurol, 2012, 11(8):669-678.

Curtis C, Gamez JE, Singh U, et al. Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density[J]. JAMA Neurol, 2015, 72(3):287-294.

Sabri O, Becker GA, Meyer PM, et al. First-in-human PET quantification study of cerebral a4β2*nicotinic acetylcholine receptors using the novel specific radioligand(-)-18F-flubatine[J]. Neuroimage, 2015, 118:199-208.

Sabri O, Sabbagh MN, Seibyl J, et al. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 study[J]. Alzheimers Dement, 2015, 11(8):964-974.

Rice L, Bisdas S. The diagnostic value of FDG and amyloid PET in Alzheimer's disease: a systematic review[J]. Eur J Radiol, 2017, 94:16-24.

Matsuda H, Shigemoto Y, Sato N. Neuroimaging of Alzheimer's disease: focus on amyloid and tau PET[J]. Jpn J Radiol, 2019, 37(11):735-749.

张政伟, 朱建华, 姚志文, 等. 淀粉样蛋白显像剂11C-PIB的自动化制备优化及临床初步应用[J]. 同位素, 2017, 30(1):23-28.

任树华, 黄琪, 胡静超, 等. 18F AV45 PET显像在轻微认知下降和轻度认知障碍患者中的应用[J]. 中华核医学与分子影像杂志, 2020, 40(4):196-200.

中华医学会核医学分会, 北京认知神经科学学会. 淀粉样蛋白PET脑显像技术规范专家共识[J]. 中华核医学与分子影像杂志, 2020, 40(12):736-742.

左传涛, 张慧玮, 管一晖. 以阿尔茨海默病相关异常蛋白沉积为靶点的PET显像[J]. 中华核医学与分子影像杂志, 2020, 40(4):193-195.

Goedert M, Eisenberg DS, Crowther RA. Propagation of tau aggregates and neurodegeneration[J]. Annu Rev Neurosci, 2017, 40:189-210.

王敏, 鲁佳荧, 李玲, 等. 基于18F-APN-1607 PET显像的阿尔茨海默病tau蛋白脑网络及偏侧性研究[J]. 中华核医学与分子影像杂志, 2021, 41(1):28-34.

Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes[J]. Acta Neuropathol, 1991, 82(4):239-259.

Thompson PW, Ye L, Morgenstern JL, et al. Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer's disease pathologies[J]. J Neurochem, 2009, 109(2):623-630.

Leuzy A, Chiotis K, Lemoine L, et al. Tau PET imaging in neurodegenerative tauopathies-still a challenge[J]. Mol Psychiatry, 2019, 24(8):1112-1134.

Sanabria-Bohorquez S, Marik J, Ogasawara A, et al. 18F-GTP1(genentech tau probe 1), a radioligand for detecting neurofibrillary tangle tau pathology in Alzheimer's disease[J]. Eur J Nucl Med Mol Imaging, 2019, 46(10):2077-2089.

Tagai K, Ono M, Kubota M, et al. High-contrast in vivo imaging of tau pathologies in Alzheimer's and non-Alzheimer's disease tauopathies[J]. Neuron, 2021, 109(1):42-58.e48.

Chiotis K, Saint-Aubert L, Savitcheva I, et al. Imaging in-vivo tau pathology in Alzheimer's disease with THK5317 PET in a multimodal paradigm[J]. Eur J Nucl Med Mol Imaging, 2016, 43(9):1686-1699.

Harada R, Okamura N, Furumoto S, et al. 18F-THK-5117 PET for assessing neurofibrillary pathology in Alzheimer's disease[J]. Eur J Nucl Med Mol Imaging, 2015, 42(7):1052-1061.

李明, 鲁佳荧, 李玲, 等. 18F-APN-1607 PET在痴呆患者脑内tau蛋白显像中的初步临床应用[J]. 中国临床神经科学, 2020, 28(5):488-493.

宁健豪, 蒋皆恢, 刘春花, 等. 基于18F-APN-1607 PET影像的阿尔茨海默病tau蛋白沉积相关疾病模式探究[J]. 中华核医学与分子影像杂志, 2020, 40(4):213-218.

Braak H, Thal DR, Ghebremedhin E, et al. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years[J]. J Neuropathol Exp Neurol, 2011, 70(11):960-969.

Cho H, Choi JY, Hwang MS, et al. Tau PET in Alzheimer disease and mild cognitive impairment[J]. Neurology, 2016, 87(4):375-383.

Ossenkoppele R, Rabinovici GD, Smith R, et al. Discriminative accuracy of18F-flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders[J]. JAMA, 2018, 320(11):1151-1162.

Ossenkoppele R, Smith R, Ohlsson T, et al. Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease[J]. Neurology, 2019, 92(6):e601-e612.

鲁佳荧, 蒋皆恢, 王敏, 等. 阿尔茨海默病患者脑内tau蛋白分布与认知组分相关性的PET显像研究[J]. 中国临床神经科学, 2020, 28(4):396-404.

Lu J, Bao W, Li M, et al. Associations of18F-APN-1607 tau PET binding in the brain of Alzheimer's disease patients with cognition and glucose metabolism[J]. Front Neurosci, 2020, 14:604.

Jellinger KA. Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies[J]. J Neural Transm(Vienna), 2018, 125(4):615-650.

JrJack CR, Bennett DA, Blennow K, et al. NIA-AA research framework: toward a biological definition of Alzheimer's disease[J]. Alzheimers Dement, 2018, 14(4):535-562.

张慧玮, 左传涛, 管一晖. 重视大数据时代下阿尔茨海默病脑内异常蛋白沉积的多维度PET显像研究[J]. 中华核医学与分子影像杂志, 2021, 41(1):2-5.

Gleason A, Ayton S, Bush AI. Unblinded by the light: amyloid-related imaging abnormalities in Alzheimer's clinical trials[J]. Eur J Neurol, 2021, 28(1):e1.

Vaz M, Silvestre S. Alzheimer's disease: recent treatment strategies[J]. Eur J Pharmacol, 2020, 887:173554.

Jiang JH, Zhou HC, Duan HQ, et al. A novel individual-level morphological brain networks constructing method and its evaluation in PET and MR images[J]. Heliyon, 2017, 3(12):e00475.

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Computed tomography signs of pheochromocytomas and paragangliomas with different biochemical phenotypes: a comparative study

Research progress in the diagnosis and treatment of non-eosinophilic asthma

Clinical features and treatment outcome of scrotal abscess: an analysis of 24 cases

Diagnosis and treatment strategies for retroperitoneal vascular leiomyosarcoma

Clinical features，diagnosis，and treatment of chlamydia psittaci pneumonia based on metagenomic next-generation sequencing: an analysis of 15 cases

Related Author

Zhao Xiaofang

Yang Ping

Liu Liu

Li Qingshu

Li Yi

Tao Fengming

Mao Yun

Zhang Xinyue

Related Institution

Department of Radiology，The First Affiliated Hospital of Chongqing Medical University

Teaching and Research Section of Pathology，College of Basic Medical Sciences，Chongqing Medical University

Department of Traditional Chinese Medicine，Children’s Hospital，Zhejiang University School of Medicine/ National Clinical Research Center for Child Health

Department of Pediatrics，The Affiliated Hospital of Nanjing University of Chinese Medicine，The First Clinical Medical College of Nanjing University of Chinese Medicine

Department of Respiratory Medicine，Children’s Hospital，Zhejiang University School of Medicine/ National Clinical Research Center for Child Health

⁰